Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis
Researchers at Phoenix Children’s identified a fibrosis-associated pericyte population absent from healthy lungs and its regulator, FOXF1. Tatiana Kalin, MD, PhD, and Vlad Kalinichenko, MD, PhD, explain the preclinical findings published in Nature Communications.
Clinical Scorecard: Fibrotic Pericytes and FOXF1 in Pulmonary Fibrosis
At a Glance
Category
Detail
Condition
Pulmonary fibrosis, including fibrosis associated with pediatric hematopoietic cell transplantation (HCT)
Key Mechanisms
A pericyte subset found in fibrotic lungs expresses scar-related genes and reduced FOXF1. In preclinical experiments, pericyte FOXF1 influenced signaling to fibroblasts and lung fibrosis.
Target Population
People with pulmonary fibrosis; pediatric HCT recipients are a clinical context discussed in the article. The FOXF1 findings are preclinical.
Care Setting
Pulmonology and post-HCT care; the reported FOXF1 target findings come from human lung datasets, laboratory experiments, and mouse models, not clinical treatment trials.
Key Highlights
Single-cell analysis identified Peri2 pericytes in fibrotic, but not healthy, lungs; these cells expressed collagen and other scar-related genes.
Reduced FOXF1 in pericytes was observed in human pulmonary fibrosis data and in mice with lung injury.
In mouse models, removing pericyte FOXF1 worsened fibrosis, while raising it reduced fibrosis and improved measured outcomes, including oxygen levels.
Laboratory experiments indicated that pericytes can influence fibroblast movement, proliferation, and scar-related gene activity.
The findings are preclinical and do not establish that FOXF1-directed treatment benefits patients.
Guideline-Based Recommendations
Diagnosis
The article describes Peri2 identification using single-cell RNA sequencing and confirmation with tissue staining; it does not provide a clinical diagnostic recommendation.
Management
The article reports that nintedanib, pirfenidone, and nerandomilast slow lung-function loss, but does not show restoration of lung architecture.
Lung transplantation is described as the only option that changes the disease course for eligible patients.
FOXF1-directed approaches are investigational; the article states that clinical trials must support the research direction.
Monitoring & Follow-up
The article provides no FOXF1-specific patient monitoring protocol.
It reports that post-HCT pulmonary fibrosis may appear years after transplant; PPFE is described as typically appearing several years after HCT.
Risks
The article describes pediatric HCT-associated PPFE as often fatal and reports an association with post-transplant pneumonia (hazard ratio 10.78).
Conditioning-regimen toxicity, including busulfan, and chronic graft-versus-host disease are described as possible causes of chronic interstitial pneumonia with fibrosis.
The article notes that FOXF1 functions in other cell types, making safety assessment necessary for potential targeted treatment.
Patient & Prescribing Data
The human analysis included a public single-cell dataset of 49 donor lungs and 67 pulmonary fibrosis lungs. The article also discusses pediatric HCT recipients; it provides no patient prescribing cohort for FOXF1-directed treatment.
No FOXF1-directed treatment has been established for patients. Raising FOXF1 reduced fibrosis in mice, including when initiated after scarring began; the article states that patient benefit has not been demonstrated.
Clinical Best Practices
Interpret the FOXF1 findings as preclinical rather than evidence of an effective patient treatment.
The article identifies post-HCT pulmonary fibrosis as a clinical concern and describes PPFE as a fibrotic complication reported in pediatric HCT recipients.
Before clinical trials, the article identifies further work on drug targets, testing in patient lung tissue and additional animal models, pericyte-specific delivery, and safety.
UK pilot study finds that whole genome sequencing can uncover genetic conditions in children, leading to changes in clinical management and specialist care